1. Proteomic Expression Changes in Large Cerebral Arteries After Experimental Subarachnoid Hemorrhage in Rat Are Regulated by the MEK-ERK1/2 Pathway
- Author
-
Janne Nielsen, Karin Warfvinge, Anne Holt Müller, Martin R. Larsen, Lars Edvinsson, Alistair V G Edwards, and Gro Klitgaard Povlsen
- Subjects
Male ,Proteomics ,0301 basic medicine ,MAPK/ERK pathway ,Pathology ,medicine.medical_specialty ,Subarachnoid hemorrhage ,Proteome ,MAP Kinase Signaling System ,MEK1/2 inhibition ,Cerebral arteries ,Ischemia ,Pharmacology ,Biology ,Article ,Rats, Sprague-Dawley ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Nitriles ,Butadienes ,medicine ,Animals ,Animal model ,cardiovascular diseases ,Enzyme Inhibitors ,Intracranial pressure ,Mitogen-Activated Protein Kinase 1 ,Mitogen-Activated Protein Kinase 3 ,Mass spectrometry ,Kinase ,General Medicine ,Cerebral Arteries ,Subarachnoid Hemorrhage ,medicine.disease ,Pathophysiology ,Rats ,nervous system diseases ,030104 developmental biology ,Cerebral blood flow ,SAH ,030217 neurology & neurosurgery - Abstract
Subarachnoid hemorrhage (SAH) is a serious clinical condition where leakage of blood into the subarachnoid space causes an acute rise in intracranial pressure and reduces cerebral blood flow, which may lead to delayed cerebral ischemia and poor outcome. In experimental SAH, we have previously shown that the outcome can be significantly improved by early inhibition of the MAPK/ERK kinase/extracellular signal-regulated kinase (MEK/ERK1/2) pathway. The aim of this study was to apply mass spectrometry to investigate the overall late effects of experimental SAH on cerebrovascular protein expression. SAH was induced in rats that were treated with the MEK1/2 inhibitor U0126 or vehicle. Neurological outcome was assessed using a battery of behavioral tests. Specific protein expression of large cerebral arteries was analyzed quantitatively with high-throughput tandem mass spectrometry. SAH resulted in a marked reduction of neurological scores, which was counteracted by U0126 treatment. Mass spectrometry analysis demonstrated regulation of 184 proteins after SAH, regulations that were in part prevented by U0126 treatment. Network analysis identified several protein networks including a strong structural network centered around 14-3-3. Additionally, protein networks with functions in mRNA metabolism and protein folding were identified. Treatment with U0126 inhibited cerebral vessel wall pERK1/2 expression and significantly improved outcome of the rats. In conclusion, we show that SAH induces a broad array of specific changes in the overall protein networks in cerebral artery smooth muscle cells and suggest that this is essential for understanding the vascular pathophysiology after SAH. Electronic supplementary material The online version of this article (doi:10.1007/s12031-017-0944-7) contains supplementary material, which is available to authorized users.
- Published
- 2017